/Dexcom%20Inc%20logo%20on%20sign-by%20Michael%20Vi%20via%20Shutterstock.jpg)
San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. Valued at a market capitalization of $28.1 billion, the company’s offerings include Dexcom G7, G7 15 Day, Dexcom G6, Dexcom ONE+, and more.
Companies with a market capitalization of $10 billion or more are typically referred to as "large-cap stocks." DXCM fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the medical devices industry.